Phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in myelodysplastic syndrome (MDS) after treatment with hypomethylating agents

TPS7103 Background: Myelodysplastic syndrome (MDS) is a group of clonal bone marrow disorders associated with an increased risk of transformation to acute myeloid leukemia (AML). Despite recent pro...